233 related articles for article (PubMed ID: 29332128)
21. Effects of prostanoid EP agonists on mouse intraocular pressure.
Saeki T; Ota T; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2201-8. PubMed ID: 19117925
[TBL] [Abstract][Full Text] [Related]
22. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
[TBL] [Abstract][Full Text] [Related]
23. Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells.
Yamamoto Y; Taniguchi T; Inazumi T; Iwamura R; Yoneda K; Odani-Kawabata N; Matsugi T; Sugimoto Y; Shams NK
J Ocul Pharmacol Ther; 2020 Apr; 36(3):162-169. PubMed ID: 31934812
[No Abstract] [Full Text] [Related]
24. Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis.
Kuo HT; Yeh CY; Hsu AY; Ho JH; Lin CJ; Tsai YY
J Ocul Pharmacol Ther; 2023 Dec; 39(10):705-715. PubMed ID: 37579061
[No Abstract] [Full Text] [Related]
25. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow.
Woodward DF; Nilsson SF; Toris CB; Kharlamb AB; Nieves AL; Krauss AH
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3320-8. PubMed ID: 19234340
[TBL] [Abstract][Full Text] [Related]
26. IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys.
Yamane S; Karakawa T; Nakayama S; Nagai K; Moriyuki K; Neki S; Suto F; Kambe T; Hirota Y; Kawabata K
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2547-52. PubMed ID: 25788650
[TBL] [Abstract][Full Text] [Related]
27. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
[TBL] [Abstract][Full Text] [Related]
28. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
[TBL] [Abstract][Full Text] [Related]
29. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
Wang RF; Gagliuso DJ; Mittag TW; Podos SM
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
[TBL] [Abstract][Full Text] [Related]
30. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
[TBL] [Abstract][Full Text] [Related]
31. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
Akaishi T; Shimazaki A; Tonouchi A; Ueda K; Miyawaki N; Kawazu K
J Ocul Pharmacol Ther; 2015 Nov; 31(9):518-24. PubMed ID: 26325164
[TBL] [Abstract][Full Text] [Related]
32. Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension.
Shiratori N; Nishio Y; Takeda A; Sugimoto S; Takazawa K; Otsuka N; Ishida N; Shii D; Hori K; Nakamoto K
Clin Ophthalmol; 2021; 15():3997-4003. PubMed ID: 34675468
[TBL] [Abstract][Full Text] [Related]
33. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
[TBL] [Abstract][Full Text] [Related]
34. The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice.
Esaki Y; Katsuta O; Kamio H; Noto T; Mano H; Iwamura R; Yoneda K; Odani-Kawabata N; Morishima K; Shams NK
J Ocul Pharmacol Ther; 2020 Sep; 36(7):529-533. PubMed ID: 32412835
[No Abstract] [Full Text] [Related]
35. A comparative study of topical natural ergot alkaloids on the intraocular pressure and aqueous humor dynamics in oclular normotensive and alpha-chymotrypsin-induced ocular hypertensive rabbits.
Puras G; Santafé J; Segarra J; Garrido M; Melena J
Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1559-67. PubMed ID: 17505840
[TBL] [Abstract][Full Text] [Related]
36. Ocular hypotensive and aqueous outflow-enhancing effects of AL-3037A (sodium ferri ethylenediaminetetraacetate).
Pang IH; Moll H; McLaughlin MA; Knepper PA; De Santis L; Epstein DL; Clark AF
Exp Eye Res; 2001 Dec; 73(6):815-25. PubMed ID: 11846512
[TBL] [Abstract][Full Text] [Related]
37. Prostanoid Receptor Antagonist Effects on Intraocular Pressure, Supported by Ocular Biodisposition Experiments.
Woodward DF; Wenthur SL; Rudebush TL; Fan S; Toris CB
J Ocul Pharmacol Ther; 2016 Nov; 32(9):606-622. PubMed ID: 27763812
[TBL] [Abstract][Full Text] [Related]
38. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys.
Chien FY; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2003 Jan; 121(1):87-90. PubMed ID: 12523891
[TBL] [Abstract][Full Text] [Related]
39. The role of EP
Bertrand JA; Woodward DF; Sherwood JM; Wang JW; Overby DR
Br J Ophthalmol; 2021 Nov; 105(11):1610-1616. PubMed ID: 33239414
[TBL] [Abstract][Full Text] [Related]
40. Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes.
Sharif NA; Williams GW; Crider JY; Xu SX; Davis TL
J Ocul Pharmacol Ther; 2004 Dec; 20(6):489-508. PubMed ID: 15684809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
